Race Oncology Ltd has released a press release.
Race Strategic Update August 2023
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Receives Additional $1.66m R&D Tax Refund for FY 2022
- Race executes agreement with Ardena for GMP manufacturing
- Race global agreement with City of Hope to access FTO IP
- H1 2023 Preclinical and Clinical Programs Update
- Letter to Shareholders
Later from Racura Oncology
- Race Board and Management Team Changes
- Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
- Bisantrene cGMP API Manufacturing Completed at Laurus Labs
- RC220 Toxicology and Safety Pharmacology Studies Initiated
- RC220 Peripheral Infusion Safety Confirmed
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology